Heart Failure 2022: Late-breaking Science Video Collection

Published: 26 May 2022

Views:
1727
Likes:
7

Views:
1727
Likes:
7
Share:

Now Playing
Part 1 | Session 2 of 9
Findings from the Pooled Analysis of DEFINE-HF and PRESERVED-HF
Mikhail Kosiborod

Up Next
4m 47s

Part 1 | Session 3 CCM Therapy in Patients With HFpEF
Cecilia Linde
7m 13s

Part 1 | Session 4 Rebalance-HF: Catheter-Based Ablation of the GSN in Pts with HFpEF
Marat Fudim
3m 34s

Part 1 | Session 5 DELIVER Extends Benefits of Dapagliflozin to the Full Spectrum of Pts with HF
Scott Solomon
4m 19s

Part 1 | Session 6 CLOROTIC: Combined Loop With Thiazide Diuretics in Pts With Decompensated HF
Joan Carles Trullas
4m 42s

Part 1 | Session 7 HELIOS-A: Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis
Pablo Garcia-Pavia
Part 1 | Session 8 6M Results of a No-Implant Interatrial Shunt in Pts With Chronic HF
Lars H Lund
1m 20s

Part 1 | Session 9 Chronic & Acute HF Guidelines for Patients: Improving Patient Care
Tiny Jaarsma

4m 6s

Part 2 | Session 1 The Future of HF Management, HFsnEF, DELIVER, DIAMOND & More with Prof Cleland
John GF Cleland
2m 40s

Part 2 | Session 2 HF 22 Highlights: Available & New Treatments with Prof Rosano
Giuseppe Rosano
4m 5s

Part 2 | Session 3 The Role of GDMT, SGLT2 Inhibition & Beyond with Dr Kosiborod
Mikhail Kosiborod

3m 17s

Part 1 | Session 1 Novel Patch Infusor Device & Subcutaneous Furosemide in Pts with HF Joanna Osmanska

Average (ratings)

No ratings

Your rating

Overview

Heart failure management: Where are we now?

Dip into the new heart failure data presented at ESC-HF Conference 2022. Learn more about the latest research and treatment options delivered by researchers driving the field. Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.

Join globally renown faculty as they share their heart failure management highlights from 2022.

More from this programme

Part 1

Expert Interviews

Short, accessible expert Interviews with select faculty focusing on the results, applicability, and impact on future research.

9 sessions
Novel Patch Infusor Device & Subcutaneous Furosemide in Pts with HF	Watch now
Findings from the Pooled Analysis of DEFINE-HF and PRESERVED-HF	Watch now
CCM Therapy in Patients With HFpEF	Watch now
Rebalance-HF: Catheter-Based Ablation of the GSN in Pts with HFpEF	Watch now
DELIVER Extends Benefits of Dapagliflozin to the Full Spectrum of Pts with HF	Watch now
CLOROTIC: Combined Loop With Thiazide Diuretics in Pts With Decompensated HF	Watch now
HELIOS-A: Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis	Watch now
6M Results of a No-Implant Interatrial Shunt in Pts With Chronic HF	Watch now
Chronic & Acute HF Guidelines for Patients: Improving Patient Care	Watch now

Part 2

Highlight Summaries

3 sessions
The Future of HF Management, HFsnEF, DELIVER, DIAMOND & More with Prof Cleland	Watch now
HF 22 Highlights: Available & New Treatments with Prof Rosano	Watch now
The Role of GDMT, SGLT2 Inhibition & Beyond with Dr Kosiborod	Watch now

Faculty Biographies

Mikhail Kosiborod

Cardiologist

Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.

He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.

Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

View full profile